Kazmira Launches Innovative Telehealth Platform for Prescription Cannabis in Colorado

In a groundbreaking development for cannabis care, Kazmira Therapeutics has officially launched Cope Now, a pioneering telehealth platform designed to provide regulated access to prescription cannabidiol (CBD) in Colorado. This launch follows Kazmira's notable initiative of establishing the first pharmacy dedicated to pure compounded CBD, setting the stage for a new era in cannabis-based treatment methods.

The platform promises to redefine how patients engage with cannabinoid therapy through clinician-led telehealth consultations. These consultations aim to assess patient needs and appropriately prescribe CBD, backed by clinical oversight from Arora Health, a partner in this venture. This collaboration ensures that patients receive a safe, structured approach to accessing necessary medications.

Addressing a Critical Gap in Cannabis Care

Evidence has surfaced indicating a significant gap in the understanding and use of CBD among current users. A recent peer-reviewed study highlighted that a large portion of daily CBD consumers—54% to be exact—administer less than the clinically recommended dose of 200 to 400 mg per day. Cope Now emerges as a solution to bridge this divide, providing a system where patient evaluations lead to safe dosages needed for effective treatment.

Kazmira's co-founder and co-CEO, Pulak Sharma, expressed the company's commitment to enhancing patient access to high-quality CBD. He remarked, "The Cope Now platform provides a structured intake and evaluation process so care decisions are clinically driven, not consumer-directed." The platform is set to start accepting appointments for telemedicine consultations on May 28, allowing eligible patients in Colorado to engage with board-certified clinicians right from the comfort of their homes.

Dr. Sean Arora, co-founder and CEO of Arora Health, also supports the potential of physician-led programs like Cope Now. He articulated, "We believe physician-led cannabinoid care programs will become an important part of modern healthcare over the next decade." The emphasis on clinical oversight, continuous patient education, and structured follow-up processes are critical for maintaining effective treatment paths for patients.

Navigating the Evolving Cannabis Regulations

The introduction of Cope Now comes at a pivotal time, as Congress recently addressed the regulatory landscape surrounding hemp-derived cannabinoid products. The closure of the hemp loophole in November 2025 has restricted the sale of THC-comprising CBD products, effectively ensuring only non-intoxicating, pharmacy-grade products like those offered through Cope Now will be available in the near future. This transition is anticipated to take full effect by November 2026, underscoring the timely relevance of Kazmira's new platform as the industry navigates these changes.

In terms of operational logistics, Cope Now will initially cater to patients in Colorado, with intentions to broaden services to additional states, depending on legislative progress and market demand for regulated cannabis therapies.

The Future of CBD Care

As more patients seek effective and safe options for their health, platforms like Cope Now may play a crucial role in shaping the future of cannabis treatment. By focusing on a clinical approach, along with robust patient-provider interactions, and providing oversight to ensure compliance, Kazmira Therapeutics is setting a high standard in the telehealth space for cannabis care.

For those interested, the Cope Now platform can be accessed starting May 28, allowing patients to begin their journey towards personalized cannabis therapy seamlessly and efficiently. For more information, you can visit copenow.com to learn more about eligibility and the types of services provided.

Kazmira Therapeutics represents a significant player in the cannabinoid marketplace, standing out as the first vertically integrated company in the U.S. focused on pharmaceutical-grade cannabinoid solutions, promoting health and wellbeing through science-driven practices. Their comprehensive approach continues to align with consumer demands for more effective cannabinoid treatments, ultimately aiming to improve patient outcomes in the realm of medical cannabis.